Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 753,609
  • Shares Outstanding, K 49,417
  • Annual Sales, $ 194,130 K
  • Annual Income, $ -74,810 K
  • 60-Month Beta -0.06
  • Price/Sales 3.88
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AERI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings $-0.27 on 11/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.51
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.60
  • Prior Year 1.09
  • Growth Rate Est. (year over year) -146.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.17 +0.53%
on 10/24/22
15.25 unch
on 11/18/22
+0.07 (+0.46%)
since 10/18/22
3-Month
10.78 +41.47%
on 08/22/22
15.37 -0.78%
on 09/07/22
+3.78 (+32.96%)
since 08/18/22
52-Week
4.81 +217.05%
on 06/02/22
15.37 -0.78%
on 09/07/22
+4.98 (+48.49%)
since 11/18/21

Most Recent Stories

More News
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”)....

ALC : 90.26 (+0.33%)
AERI : 15.25 (+0.07%)
Aerie: Q3 Earnings Snapshot

Aerie: Q3 Earnings Snapshot

AERI : 15.25 (+0.07%)
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results...

AERI : 15.25 (+0.07%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, POSH, PBFX, RNWK, AERI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SBTX : 5.87 (+1.03%)
POSH : 17.90 (unch)
PBFX : 19.90 (-2.40%)
RNWK : 0.7300 (+0.03%)
AERI : 15.25 (+0.07%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSVI, AERI, BTRS, POSH

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CSVI : 57.9800 (+0.02%)
AERI : 15.25 (+0.07%)
BTRS : 9.49 (-0.11%)
POSH : 17.90 (unch)
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceuticals, Inc. (NasdaqGM: AERI)...

AERI : 15.25 (+0.07%)
ALC : 90.26 (+0.33%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, SMBC, EVOP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AERI : 15.25 (+0.07%)
SMBC : 50.50 (+6.11%)
EVOP : 33.99 (+0.38%)
SHAREHOLDER ALERT: Weiss Law Reminds SMBC, AERI, CSVI, and COWN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SMBC : 50.50 (+6.11%)
AERI : 15.25 (+0.07%)
CSVI : 57.9800 (+0.02%)
COWN : 38.99 (unch)
SHAREHOLDER ALERT: Weiss Law Reminds AERI, RCOR, STOR, and LOTZ Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AERI : 15.25 (+0.07%)
RCOR : 3.20 (+4.92%)
STOR : 32.21 (unch)
LOTZ : 0.1480 (-1.99%)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

SPSM : 45.43 (+3.51%)
CPRX : 16.99 (+1.43%)
CG : 46.51 (+5.54%)
APLS : 41.15 (+2.88%)
AERI : 15.25 (+0.07%)
BLTE : 48.55 (-0.92%)
VRNA : 22.26 (+3.53%)
RVNC : 4.25 (+11.55%)

Business Summary

Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients...

See More

Key Turning Points

3rd Resistance Point 15.26
2nd Resistance Point 15.26
1st Resistance Point 15.25
Last Price 15.25
1st Support Level 15.24
2nd Support Level 15.24
3rd Support Level 15.23

See More

52-Week High 15.37
Last Price 15.25
Fibonacci 61.8% 11.34
Fibonacci 50% 10.09
Fibonacci 38.2% 8.84
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar